Compare Heron Therapeutics Inc (HRTX) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NextEra Energy, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while NextEra Energy, Inc. trades at $88 (market cap $183.53B). The key difference: NextEra Energy, Inc. is far larger — about 2006.7× Heron Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 2.83% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NEE | |
|---|---|---|
Market Cap | $91.46M | $183.53B |
Sector | Health | Utilities |
52-Week High | $1.96 | $97.88 |
52-Week Low | $0.39 | $69.77 |
Enterprise Value | $189.36M | $285.94B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
NextEra Energy (NEE) trades at $87.82, down 1.1% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, beating estimates with $1.09 EPS versus $1.03 expected, but missed Q4 2025. Revenue for 2025 reached $27.41B with a net income margin of 29.37%. Recent news highlights a planned $59B annual capex through 2032 and a merger filing with Dominion Energy to expand market reach.
Outlook remains positive with analyst consensus price target of $101.88 (16% upside), supported by 66.7% buy ratings. Key risks include high capital expenditures straining cash flow and regulatory hurdles for the Dominion merger. The stock offers growth potential from clean energy investments but faces execution and debt concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
